Back to top
more

Endo International plc (ENDP)

(Delayed Data from NSDQ)

$8.20 USD

8.20
3,004,238

+0.48 (6.22%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can Endo (ENDP) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Teva Shares Fall Further as Morgan Stanley Downgrades Rating

by Zacks Equity Research

Shares of Teva (TEVA) are on a downtrend on the risk of high litigation costs related to opioid epidemic in the United States. Morgan Stanley downgrades its rating on Teva.

Options Traders Expect Huge Moves in Endo (ENDP) Stock

by Zacks Equity Research

Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

Why Is Endo (ENDP) Down 38.9% Since Last Earnings Report?

by Zacks Equity Research

Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Endo (ENDP) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.

Endo International (ENDP) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Endo (ENDP) delivered earnings and revenue surprises of 26.19% and 4.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

BioDelivery (BDSI) Stock Up on Q1 Earnings and Sales Beat

by Zacks Equity Research

BioDelivery (BDSI) incurs narrower-than-expected loss in Q1. Sales surpass the consensus mark. The company raises guidance for 2019.

What's in Store for Catalyst Pharma (CPRX) Q1 Earnings?

by Zacks Equity Research

Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.

    Analysts Estimate Endo International (ENDP) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    What's in Store for BioDelivery (BDSI) This Earnings Season?

    by Zacks Equity Research

    Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

    What's in Store for BioSpecifics (BSTC) This Earnings Season?

    by Zacks Equity Research

    BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.

    Why Is Endo (ENDP) Down 26.9% Since Last Earnings Report?

    by Zacks Equity Research

    Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse

    by Zacks Equity Research

    Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.

    BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up

    by Zacks Equity Research

    BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.

    Insys Plunges on Auditor's Concern About Insufficient Funds

    by Zacks Equity Research

    Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.

    Is Endo International (ENDP) a Great Stock for Value Investors?

    by Zacks Equity Research

    Is Endo International (ENDP) a great pick from the value investor's perspective right now? Read on to know more.

    Endo (ENDP) Soars: Stock Adds 6% in Session

    by Zacks Equity Research

    Endo (ENDP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

    What's in Store for BioSpecifics (BSTC) This Earnings Season?

    by Zacks Equity Research

    BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.

    Implied Volatility Surging for Endo (ENDP) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

    Endo (ENDP) Q4 Earnings & Revenues Beat Estimates, Shares Up

    by Zacks Equity Research

    Endo's (ENDP) earnings and revenues top expectations in the fourth quarter.

    Earnings Preview: Endo International (ENDP) Q4 Earnings Expected to Decline

    by Zacks Equity Research

    Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Heron Gains on Priority Review Designation for Pain Drug

    by Zacks Equity Research

    Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.

    Options Traders Expect Huge Moves in Endo (ENDP) Stock

    by Zacks Equity Research

    Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

    Generic Drugmakers Down on Allegations of Price Fixing

    by Zacks Equity Research

    An article in The Washington Post levels charges of price fixing against several generic drugmakers, driving their shares down.

    Why Is Endo (ENDP) Down 12.3% Since Last Earnings Report?

    by Zacks Equity Research

    Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.